Cyagen’s HUGO-Ab™ platform integrates fully human antibody mouse technologies, AI-powered antibody computing, in vitro functional assays, and in vivo efficacy validation to support next-generation antibody drug discovery. Built around HUGO-Mab™, HUGO-Light™, and HUGO-Nano™, the platform enables the discovery of fully human monoclonal antibodies, common light chain antibodies, and fully human single-domain antibody candidates for diverse therapeutic formats, including mAbs, bispecific antibodies, multispecific antibodies, ADCs, T-cell engagers, and cell therapy-related applications.
By connecting target discovery, antibody screening, computational analysis, functional validation, and preclinical efficacy studies, HUGO-Ab™ provides a streamlined discovery-to-validation workflow for therapeutic antibody development.
An Intelligent Antibody Computing Platform for Discovery, Optimization, and Translational Validation
AbSeek™ is Cyagen’s intelligent antibody computing platform designed to accelerate antibody drug development through the integration of artificial intelligence, bioinformatics, and Cyagen’s two decades of expertise in genetically engineered models and antibody discovery.
By integrating 30+ self-developed and open-source computational tools, AbSeekTM supports key stages of antibody R&D, including antibody sequence analysis, structure prediction, affinity optimization, immunogenicity assessment, developability evaluation, and functional validation planning.
From target intelligence and antibody design to computational screening and in vivo validation, AbSeek™ enables a more efficient, data-driven workflow for next-generation antibody therapeutics.
From target evaluation to antibody discovery strategy
As the intelligence engine of the AbSeek™ platform, AbMart seamlessly integrates global R&D pipeline data, disease-centric insights, and downstream development resources. By aggregating this critical target intelligence, AbMart empowers researchers to rapidly navigate the competitive development landscape, evaluate early-stage targets, and uncover high-value opportunities for antibody drug discovery.
- Annotate Complementarity-Determining Regions (CDRs) with high precision.
- Align antibody homology and analyze VDJ gene recombination.
- Construct sequence alignments and phylogenetic trees.
- Assess natural heavy/light-chain pairing probabilities.
- Cluster & Visualize species-specific and V-gene families.
- Identify interacting residue pairs and profile hydrophobicity.
- Predict accurate antibody 3D structures and inverse folding models.
- Simulate highly reliable antibody-antigen docking structures.
- Evaluate humanization potential and in silico binding affinities.
- Predict highly specific B-cell epitopes.
- Analyze physicochemical properties and assess overall structural stability.
- Profile critical developability-related features early in the pipeline.
- Engineer in silico affinity maturation and humanization workflows.
- Optimize hydrophobicity to enhance downstream developability.
- Generate antigen-guided, novel antibody sequences de novo.
- Design AI-assisted antibody candidates ready for downstream screening and empirical validation.
Cyagen’s HUGO-Ab™ fully human antibody mouse platform is designed to support therapeutic antibody discovery across a broad range of antibody drug formats, including monoclonal antibodies, bispecific and multispecific antibodies, antibody-drug conjugates, T-cell engagers, and fully human single-domain antibody candidates.
Rather than a single mouse model, the HUGO-Ab™ platform consists of three functionally differentiated product series: HUGO-Mab™, HUGO-Light™, and HUGO-Nano™. Together, they eliminate critical bottlenecks in biologic development, including candidate developability, heavy/light-chain mispairing, and the structural limitations of conventional IgGs.
Seamlessly integrated with our AI-powered AbSeek™ algorithms and in vivo efficacy models, HUGO-Ab™ accelerates your workflow from initial antigen strategy to IND-enabling translational evaluation.
Empowering High-Affinity, Fully Human Biologic Discovery
Developed via our proprietary TurboKnockout™ gene-editing technology, HUGO-Mab™ features precise in situ replacement of murine immunoglobulin variable regions with human repertoires.
Overcoming the Mispairing Bottleneck for Bispecific Therapeutics
HUGO-Light™ is specifically engineered to streamline complex multispecific formats. By inserting a pre-fixed, rearranged human light-chain variable sequence and inactivating endogenous light-chain genes, the model restricts immune responses to a shared common light chain.
Compact, Flexible, and Fully Human Single-Domain Solutions
Engineered for applications demanding compact molecular size and deep tissue penetration, HUGO-Nano™ directly generates fully human heavy-chain-only antibodies.
Breaking lmmune Tolerance for Highly Conserved Targets
For targets exhibiting high human-mouse sequence homology, immune tolerance often stifles antibody discovery. The HUGO-Ab-eKO™ platform swiftly knocks out the murine homolog on a fully human antibody background. By eliminating the endogenous antigen, it breaks immune tolerance.ensuring robust human-target recognition and high-titer responses against your most challenging therapeutic targets.
Cyagen delivers comprehensive in vitro efficacy validation services to enable rigorous evaluation of antibody binding kinetics, functional potency, immune effector functions, and species cross-reactivity. Leveraging our advanced cell engineering and reporter assay platforms, we provide the highly predictive data required to accelerate candidate prioritization and de-risk downstream preclinical development. To drive your therapeutic discovery, we offer a robust portfolio of engineered reporter cell lines and humanized cellular models derived from validated backgrounds (e.g., Jurkat, HEK293). These systems can be rapidly custom-engineered to express immune checkpoints, GPCRs, and metabolic targets, ensuring highly sensitive and mechanistically relevant functional readouts.
| Service Category | Assay Capabilities | Research Applications |
|---|---|---|
| Binding Activity Assessment | Protein- and, cell-based binding assay (e.g., FACS), species cross-reactivity profiling | Evaluate target engagement confirm specificity, and support candidate ranking |
| Affinity Measurement | Binding kinetics via BLI, KD determination | Quantify binding affinities to prioritize top therapeutic leads |
| Functional Activity Assays | Neutralization assay, blocking assay, pathway activation/inhibition assay | Assess antibody-mediated functional responses and elucidate mechanism of action |
| Immune Effector Function | ADCC activity assay, Cytotoxicity assay | Evaluate immune-cell recruitment efficacy and functional potency |
| Internalization Assay | Antibody internalization activity assay | Support ADCs, bispecific ADCs, and targeted delivery vehicles |
| Reporter Gene Assays | Luciferase reporter systems engineered in robust backgrounds (e.g.,Jurkat, HEK293) | Quantify immune checkpoint engagement, T-cell activation, GPCR signaling, and target-specific pathway modulation |
Cyagen’s integrated in vivo pharmacology platform accelerates the clinical translation of novel therapeutics through robust efficacy, mechanism-of-action (MoA), and early safety evaluations. Anchored by an extensive portfolio of disease-relevant models—including HUGO-GT™ genomic humanized, immune-reconstituted (huPBMC/huHSC), and highly immunodeficient strains—we deliver definitive in vivo data across oncology, immunology, and neurology indications.
Optimized for complex modalities such as bispecific antibodies (bsAbs), ADCs, and cell therapies, our humanized systems yield highly predictive readouts. From deep immune activation profiling to Cytokine Release Syndrome (CRS) risk assessments, we generate the IND-enabling insights required to maximize your pipeline's clinical success.
| Study Category | Key Readouts & Assays | Research Applications |
|---|---|---|
| Efficacy Evaluation | Tumor growth inhibition (TGI), lesion scoring, survival analysis, disease phenotype improvement, and longitudinal body weight monitoring. | Assess in vivo therapeutic efficacy of antibody candidates across oncology, inflammatory, metabolic, ophthalmological, and neurological disease models. |
| Pharmacodynamic (PD) Analysis | Target engagement, pathway modulation, biomarker expression, receptor occupancy (RO), and tissue-level response profiling. | Support critical mechanism-of-action (MoA) studies and robust preclinical candidate selection |
| Immune Cell Activation Profiling | Flow cytometry, comprehensive immune cell profiling, T-cell/NK cell activation, myeloid cell analysis, and tumor-infiltrating lymphocyte (TIL) assessment. | Evaluate immuno-oncology (IO) therapeutics, bispecific antibodies (bsAbs), T-cell engagers (TCEs), and novel cell therapy. |
| Cytokine Profiling | Serum cytokine quantification, multiplex inflammatory cytokine panels, and Cytokine Release Syndrome (CRS) risk assessment. | Support deep immune activation studies and de-risk crucial CRS liabilities for systemic therapeutics. |
| Histology & Tissue Analysis | H&E staining, Immunohistochemistry (IHC), Immunofluorescence (IF), pathological scoring, and biodistribution mapping. | Assess tissue-level efficacy, spatial immune cell infiltration, target engagement, and morphological toxicity |
| Safety-Related Assessment | Clinical observations, body/organ weights, comprehensive serum chemistry, hematology, and detailed tissue pathology. | Evaluate early safety profiles to inform and de-risk downstream IND-enabling toxicology studies. |
| Bispecific Antibody (bsAb) Validation | Custom integration of target-humanized and Humanized Immune System (HIS) models, paired with immune activation and off-target toxicity readouts | Deliver tailored in vivo validation for bsAbs, T-cell engagers (TCEs), immune checkpoint inhibitors, and other complex multispecifics |
